Nuvectis Pharma announced that the U.S. Food and Drug Administration ("FDA") cleared the Company's Investigational New Drug Application ("IND") for NXP900, which includes the Phase 1 clinical trial protocol.
In preclinical studies, NXP900 demonstrated robust single agent antitumor activity in several in vivo xenograft models, including in squamous cell cancers such as cervical, head and neck and esophageal carcinomas in which Hippo pathway mutations and copy number abnormalities are prevalent.
In addition, NXP900 in combination with osimertinib (the active ingredient in TAGRISSO
